Belvedere Trading
DYN icon

Belvedere Trading’s Dyne Therapeutics DYN Stock Holding History

Belvedere Trading’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-400
Closed -$11.4K – 755
2024
Q1 		$11.4K Sell
400
-3,000
-88% -$67.8K ﹤0.01% 599
2023
Q4 		$45.2K Buy
3,400
+3,200
+1,600% +$31.3K ﹤0.01% 586
2023
Q3 		$1.79K Buy
+200
New +$2.15K ﹤0.01% 588

Other funds holding DYN

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Belvedere Trading's DYN Position: Q2 2024 in Review

Belvedere Trading sold out of Dyne Therapeutics (DYN) in Q2 2024, closing a stake of 1,807 shares — an estimated $51.3K sold.

Belvedere Trading first reported a position in DYN in Q3 2023 and held it in 3 quarters. The position peaked at $462K in Q4 2023. 193 funds tracked by Wall St. Rank hold DYN as of Q2 2024.

  • Belvedere Trading reported no remaining Dyne Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Belvedere Trading sold 1,807 Dyne Therapeutics shares in Q2 2024, an estimated $51.3K.
  • Belvedere Trading first reported a position in Dyne Therapeutics in Q3 2023 and held it in 3 quarters.
  • Belvedere Trading's Dyne Therapeutics position peaked at $462K in Q4 2023.
  • 193 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2024.

Based on Belvedere Trading's 13F filing for Q2 2024, filed 9 Aug 2024.